Sol-Gel Technologies Total Current Liabilities 2016-2024 | SLGL
Sol-Gel Technologies total current liabilities from 2016 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Sol-Gel Technologies Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$5 |
| 2022 |
$3 |
| 2021 |
$12 |
| 2020 |
$6 |
| 2019 |
$7 |
| 2018 |
$5 |
| 2017 |
$67 |
| 2016 |
$42 |
| 2015 |
$19 |
Sol-Gel Technologies Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$5 |
| 2024-03-31 |
$5 |
| 2023-12-31 |
$5 |
| 2023-09-30 |
$5 |
| 2023-06-30 |
$6 |
| 2023-03-31 |
$4 |
| 2022-12-31 |
$3 |
| 2022-09-30 |
$3 |
| 2022-06-30 |
$3 |
| 2022-03-31 |
$4 |
| 2021-12-31 |
$12 |
| 2021-09-30 |
$10 |
| 2021-06-30 |
$5 |
| 2021-03-31 |
$4 |
| 2020-12-31 |
$6 |
| 2020-09-30 |
$7 |
| 2020-06-30 |
$7 |
| 2020-03-31 |
$7 |
| 2019-12-31 |
$7 |
| 2019-09-30 |
$8 |
| 2019-06-30 |
$7 |
| 2019-03-31 |
$8 |
| 2018-06-30 |
$4 |
| 2018-03-31 |
$2 |
| 2017-12-31 |
|
| 2017-09-30 |
$71 |
| 2017-06-30 |
|
| 2016-12-31 |
$42 |
| 2015-12-31 |
$19 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.015B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
